MetaCap

Liminatus Pharma (LIMN) vs Scilex (SCLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scilex is the larger company by market cap ($4.0 million vs $3.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LIMN-35.31%SCLX-83.79%
+4%-42%-88%
Oct 7, 20261 yearNov 20, 2026
LIMN-33.24%SCLX-80.62%
+4%-40%-85%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LIMN versus SCLX key metrics
MetricLIMNSCLX
Share price$2.51$0.5658
Market cap$3.37M$3.98M
1-day change-10.68%-12.95%
YTD return—-92.55%
1-year return—-95.96%
5-year return—-99.74%
Forward P/E—0.78
EPS (TTM)$-23.50$-49.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$30.25M
Revenue growth (YoY)—-46.54%
Net income (latest FY)$-10.21M$-374.05M
Gross margin—415.83%
Operating margin—-1143.71%
Net margin—-1236.42%
52-week high$141.50$14.34
52-week low$2.40$0.50
Distance from 52-week high-98.23%-96.05%
Average volume30.88K56.11K
Shares outstanding1.34M7.03M
Employees134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Liminatus Pharma

LIMN stock →

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees

About Scilex

SCLX stock →

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

LIMN vs SCLX FAQ

Which is bigger, Liminatus Pharma or Scilex?

Scilex (SCLX) is larger, with a market capitalization of $3.98M compared with $3.37M for Liminatus Pharma (LIMN).

Are Liminatus Pharma and Scilex in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons